{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:09:08Z","timestamp":1761808148669},"reference-count":25,"publisher":"Tohoku University Medical Press","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tohoku J. Exp. Med."],"published-print":{"date-parts":[[2017]]},"DOI":"10.1620\/tjem.242.115","type":"journal-article","created":{"date-parts":[[2017,6,15]],"date-time":"2017-06-15T18:09:53Z","timestamp":1497550193000},"page":"115-120","source":"Crossref","is-referenced-by-count":21,"title":["Efficacy of Denosumab for Osteoporosis in Three Female Patients with Osteogenesis Imperfecta"],"prefix":"10.1620","volume":"242","author":[{"given":"Masashi","family":"Uehara","sequence":"first","affiliation":[{"name":"Department of Orthopaedic Surgery, Shinshu University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukio","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Shinshu University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Shinshu University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikio","family":"Kamimura","sequence":"additional","affiliation":[{"name":"Center of Osteoporosis and Spinal Disorders, Kamimura Orthopedic Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shota","family":"Ikegami","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Shinshu University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takako","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Shinshu University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeharu","family":"Uchiyama","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Shinshu University School of Medicine"},{"name":"Department of Orthopaedic Surgery, Okaya City Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomomi","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Department of Medical Genetics, Shinshu University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoki","family":"Kosho","sequence":"additional","affiliation":[{"name":"Department of Medical Genetics, Shinshu University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Shinshu University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"622","reference":[{"key":"1","unstructured":"Barnes, A.M., Chang, W., Morello, R., Cabral, W.A., Weis, M., Eyre, D.R., Leikin, S., Makareeva, E., Kuznetsova, N., Uveges, T.E., Ashok, A., Flor, A.W., Mulvihill, J.J., Wilson, P.L., Sundaram, U.T., Lee, B. &amp; Marini, J.C. (2006) Deficiency of cartilage-associated protein in recessive lethal osteogenesis imperfecta. <i>N. Engl. J. Med.<\/i>, 355, 2757-2764."},{"key":"2","doi-asserted-by":"crossref","unstructured":"Bishop, N., Adami, S., Ahmed, S.F., Ant\u00f3n, J., Arundel, P., Burren, C.P., Devogelaer, J.P., Hangartner, T., Hossz\u00fa, E., Lane, J.M., Lorenc, R., M\u00e4kitie, O., Munns, C.F., Paredes, A., Pavlov, H., et al. (2013) Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial. <i>Lancet<\/i>, 382, 1402-1432.","DOI":"10.1016\/S0140-6736(13)61091-0"},{"key":"3","unstructured":"Bone, H.G., Bolognese, M.A., Yuen, C.K., Kendler, D.L., Miller, P.D., Yang, Y.C., Grazette, L., San Martin, J. &amp; Gallagher, J.C. (2011) Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. <i>J. Clin. Endocrinol. Metab.<\/i>, 96, 972-980."},{"key":"4","unstructured":"Fazil, M., Baboota, S., Sahni, J.K., Ameeduzzafar, &amp; Ali, J. (2015) Bisphosphonates: therapeutics potential and recent advances in drug delivery. <i>Drug Deliv.<\/i>, 22, 1-9."},{"key":"5","doi-asserted-by":"crossref","unstructured":"Forlino, A. &amp; Marini, J.C. (2016) Osteogenesis imperfecta. <i>Lancet<\/i>, 387, 1657-1671.","DOI":"10.1016\/S0140-6736(15)00728-X"},{"key":"6","unstructured":"Glorieux, F.H., Bishop, N.J., Plotkin, H., Chabot, G., Lanoue, G. &amp; Travers, R. (1998) Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. <i>N. Engl. J. Med.<\/i>, 339, 947-952."},{"key":"7","unstructured":"Hoyer-Kuhn, H., Franklin, J., Allo, G., Kron, M., Netzer, C., Eysel, P., Hero, B., Schoenau, E. &amp; Semler, O. (2016) Safety and efficacy of denosumab in children with osteogenesis imperfect: a first prospective trial. <i>J. Musculoskelet. Neuronal Interact.<\/i>, 16, 24-32."},{"key":"8","unstructured":"Hoyer-Kuhn, H., Netzer, C., Koerber, F., Schoenau, E. &amp; Semler, O. (2014) Two years\u2019 experience with denosumab for children with osteogenesis imparcta type VI. <i>Orphanet J. Rare Dis.<\/i>, 9, 145."},{"key":"9","unstructured":"Kamimura, M., Nakamura, Y., Ikegami, S., Uchiyama, S., Kato, H. &amp; Taguchi, A. (2017) Significant improvement of bone mineral density and bone turnover markers by denosumab therapy in bisphosphonate-unresponsive patients. <i>Osteoporos. Int.<\/i>, 28, 559-566."},{"key":"10","doi-asserted-by":"crossref","unstructured":"Land, C., Rauch, F., Travers, R. &amp; Glorieux, F.H. (2007) Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment. <i>Bone<\/i>, 40, 638-644.","DOI":"10.1016\/j.bone.2006.10.010"},{"key":"11","unstructured":"Lewiecki, E.M., Miller, P.D., McClung, M.R., Cohen, S.B., Bolognese, M.A., Liu, Y., Wang, A., Siddhanti, S. &amp; Fitzpatrick, L.A.; AMG 162 Bone Loss Study Group (2007) Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. <i>J. Bone Miner. Res.<\/i>, 22, 1832-1841."},{"key":"12","unstructured":"Major, C.C., Borggren, C.L. &amp; Devries, R.M. (2008) Traumatic hand fracture in a patient with osteogenesis imperfecta. <i>J. Chiropr. Med.<\/i>, 7, 155-160."},{"key":"13","doi-asserted-by":"crossref","unstructured":"Marini, J.C., Forlino, A., Cabral, W.A., Barnes, A.M., San Antonio, J.D., Milgrom, S., Hyland, J.C., K\u00f6rkk\u00f6, J., Prockop, D.J., De Paepe, A., Coucke, P., Symoens, S., Glorieux, F.H., Roughley, P.J., Lund, A.M., et al. (2007) Consortium for osteogenesis imperfecta mutations in the helical domain of type I collagen: regions rich in lethal mutations align with collagen binding sites for integrins and proteoglycans. <i>Hum. Mutat.<\/i>, 28, 209-221.","DOI":"10.1002\/humu.20429"},{"key":"14","unstructured":"McClung, M.R., Boonen, S., T\u00f6rring, O., Roux, C., Rizzoli, R., Bone, H.G., Benhamou, C.L., Lems, W.F., Minisola, S., Halse, J., Hoeck, H.C., Eastell, R., Wang, A., Siddhanti, S. &amp; Cummings, S.R. (2012) Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis. <i>J. Bone Miner. Res.<\/i>, 27, 211-218."},{"key":"15","doi-asserted-by":"crossref","unstructured":"Miller, P.D., Bolognese, M.A., Lewiecki, E.M., McClung, M.R., Ding, B., Austin, M., Liu, Y. &amp; San Martin, J.; Amg Bone Loss Study Group (2008) Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. <i>Bone<\/i>, 43, 222-229.","DOI":"10.1016\/j.bone.2008.04.007"},{"key":"16","doi-asserted-by":"crossref","unstructured":"Morello, R., Bertin, T.K., Chen, Y., Hicks, J., Tonachini, L., Monticone, M., Castagnola, P., Rauch, F., Glorieux, F.H., Vranka, J., B\u00e4chinger, H.P., Pace, J.M., Schwarze, U., Byers, P.H., Weis, M., et al. (2006) CRTAP is required for prolyl 3-hydroxylation and mutations cause recessive osteogenesis imperfecta. <i>Cell<\/i>, 127, 291-304.","DOI":"10.1016\/j.cell.2006.08.039"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Nakamura, Y., Kamimura, M., Ikegami, S., Mukaiyama, K., Uchiyama, S., Taguchi, A. &amp; Kato, H. (2015) Changes in serum vitamin D and PTH values using denosumab with or without bisphosphonate pre-treatment in osteoporotic patients: a short-term study. <i>BMC Endocr. Disord.<\/i>, 15, 81.","DOI":"10.1186\/s12902-015-0077-3"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Orimo, H., Hayashi, Y., Fukunaga, M., Sone, T., Fujiwara, S., Shiraki, M., Kushida, K., Miyamoto, S., Soen, S., Nishimura, J., Oh-Hashi, Y., Hosoi, T., Gorai, I., Tanaka, H., Igai, T. &amp; Kishimoto, H. (2001) Diagnostic criteria of primary osteoporosis: year 2000 revision. <i>Jpn. J. Bone Metab.<\/i>, 18, 76e8.","DOI":"10.1007\/s007740170001"},{"key":"19","doi-asserted-by":"crossref","unstructured":"Rauch, F. &amp; Glorieux, F.H. (2004) Osteogenesis imperfecta. <i>Lancet<\/i>, 363, 1377-1385.","DOI":"10.1016\/S0140-6736(04)16051-0"},{"key":"20","unstructured":"Semler, O., Beccard, R., Palmisano, D., Demant, A., Fricke, O., Schoenau, E. &amp; Koerber, F. (2011) Reshaping of vertebrae during treatment with Neridronate or Pamidronate in children with osteogenesis imperfecta. <i>Horm. Res. Paediatr.<\/i>, 76, 321-327."},{"key":"21","unstructured":"Semler, O., Netzer, C., Hoyer-Kuhn, H., Becker, J., Eysel, P. &amp; Schoenau, E. (2012) First use of the RANKL antibody denosumab in osteogenesis imperfecta type VI. <i>J. Musculoskelet. Neuronal Interact.<\/i>, 12, 183-188."},{"key":"22","unstructured":"Sillence, D.O., Senn, A. &amp; Danks, D.M. (1979) Genetic heterogeneity in osteogenesis imperfecta. <i>J. Med. Genet.<\/i>, 16, 101-106."},{"key":"23","doi-asserted-by":"crossref","unstructured":"Uchiyama, S., Ikegami, S., Kamimura, M., Mukaiyama, K., Nakamura, Y., Nonaka, K. &amp; Kato, H. (2015) The skeletal muscle cross sectional area in long-term bisphosphonate users is smaller than that of bone mineral density-matched controls with increased serum pentosidine concentrations. <i>Bone<\/i>, 75, 84-87.","DOI":"10.1016\/j.bone.2015.02.018"},{"key":"24","doi-asserted-by":"crossref","unstructured":"Van Dijk, F.S. &amp; Sillence, D.O. (2014) Osteogenesis imperfecta: clinical diagnosis, nomenclature and severity assessment. <i>Am. J. Med. Genet. A<\/i>, 164A, 1470-1481.","DOI":"10.1002\/ajmg.a.36545"},{"key":"25","unstructured":"Wang, H.D., Boyce, A.M., Tsai, J.Y., Gafni, R.I., Farley, F.A., Kasa-Vubu, J.Z., Molinolo, A.A. &amp; Collins, M.T. (2014) Effects of denosumab treatment and discontinuation on human growth plates. <i>J. Clin. Endocrinol. Metab.<\/i>, 99, 891-897."}],"container-title":["The Tohoku Journal of Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/tjem\/242\/2\/242_115\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,26]],"date-time":"2019-09-26T00:24:38Z","timestamp":1569457478000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/tjem\/242\/2\/242_115\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1620\/tjem.242.115","relation":{},"ISSN":["0040-8727","1349-3329"],"issn-type":[{"value":"0040-8727","type":"print"},{"value":"1349-3329","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}